



401.1013US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/500,964
Applicants: SUGASAWA, et al.
Filed: July 8, 2004
Art unit: 1625
Examiner: Celia C. CHANG
For: **2-Acylaminothiazole Derivative or Salt Thereof**
Attorney Docket No.: 401.1013US

MAIL STOP: RCE
Commissioner for Patents
Alexandria, VA 22313-1450

September 29, 2008

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.56

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents enclosed herewith for consideration by the Examiner in connection with the examination of the above-identified patent application.

In the Information Disclosure Statement submitted by Applicant on June 25, 2008, Applicant respectfully advised the Examiner of the following commonly assigned U.S. Patents and applications:

U.S. Patent No. 7,361,658, entitled "2-Acylaminothiazole Derivative or Salt Thereof", issued April 22, 2008 (filed on January 13, 2006 as U.S. Serial No. 10/564,520);

U.S. Patent Application Publication No. 2004/0077697, entitled “2-Acylaminothiazole Derivative or Salt Thereof”, published on April 22, 2004 (filed as U.S. Serial No. 10/470,917, now abandoned);

U.S. Patent Application Publication No. 2007/0203153, entitled “Compositions and Methods of Treating Thrombocytopenia”, published August 30, 2007 (filed July 11, 2006 as U.S. Serial No. 11/593,758); and

Corresponding U.S. Patent Application Publication No. 2008/0039475, entitled “Compositions and Methods for Increasing Blood Platelet Levels in Humans”, published February 14, 2008 (filed July 8, 2007 as U.S. Serial No. 11/891,133);

For completeness, in addition to referencing the above-mentioned cases, Applicants submit herewith copies of Office Actions issued from and Responses submitted to the United States Patent Office in these cases as Appendices A-D.

Also submitted herewith are copies of: (i) the International Search Report and the Written Opinion of the International Searching Authority issued in connection with related International Application No. PCT/US07/17860 (Appendix E); and (ii) the International Report on Patentability of the PCT issued in connection with related International Application No. PCT/IB2006/003142 (Appendix F).

This Information Disclosure Statement is being submitted together with a Request for Continued Examination under 37 C.F.R. § 1.114 and with the fee set forth under 37 C.F.R. § 1.17(e). It is believed that no additional fees are due for this submission. If it is determined that any additional fees are due or an overpayment has been made in connection with the filing of this submission, the Commissioner for Patents is authorized to charge said fee or to credit said overpayment to Attorney Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

Richard V. Zanzalari

Reg. No. 49,032

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th floor
New York, NY 10018
(212) 736-1940